Reply Regarding "Efficacy and Safety of Transcranial Magnetic Stimulation in the Acute Treatment of Major Depression: A Multisite Randomized Controlled Trial"

John P. O'Reardon; H. Brent Solvason; Philip G. Janicak; Shirlene Sampson; Keith E. Isenberg; Ziad Nahas; William M. McDonald; David Avery; Paul B. Fitzgerald; Colleen Loo; Mark A. Demitrack; Mark S. George; Harold A. Sackeim

doi:10.1016/j.biopsych.2009.06.027

Reply Regarding "Efficacy and Safety of Transcranial Magnetic Stimulation in the Acute Treatment of Major Depression: A Multisite Randomized Controlled Trial"

John P. O'Reardon, H. Brent Solvason, Philip G. Janicak, Shirlene Sampson, Keith E. Isenberg, Ziad Nahas, William M. McDonald, David Avery, Paul B. Fitzgerald, Colleen Loo, Mark A. Demitrack, Mark S. George, Harold A. Sackeim

Psychiatry & Behavioral Sciences

Research output: Contribution to journal › Letter › peer-review

11 Scopus citations

Original language	English (US)
Pages (from-to)	e15-e17
Journal	Biological psychiatry
Volume	67
Issue number	2
DOIs	https://doi.org/10.1016/j.biopsych.2009.06.027
State	Published - Jan 15 2010

Bibliographical note

Funding Information:
Dr. Isenberg has received grant support from the NIMH and Neuronetics; he is currently a full-time medical director at Wellpoint.

Funding Information:
Dr. Loo has received research support from the National Health and Medical Research Council (Australia), Neuronetics, New South Wales Schizophrenia Fellowship, Pfizer Neuroscience.

Funding Information:
Dr. Sackeim has received research support from the Cyberonics, MECTA, NARSAD, National Institute of Mental Health, and has acted as a consultant to Cyberonics, Eli Lilly, Magstim, MECTA, Neuronetics, NeuroPace, Novartis, and Pfizer.

Funding Information:
Dr. McDonald reports that he serves on the Executive Board of the Georgia Psychiatric Physicians Association and is Director of the Fuqua Center for Late-Life Depression, which advocate for geriatric psychiatry. Dr. McDonald is a member of the American Psychiatric Association (APA) task force on electroconvulsive therapy (ECT) and a member of the APA Council on Research. He reports consultant/speaker honorarium from Myriad, Bristol-Myers Squibb, and Janssen. He has received grant support from Boehinger Ingelheim and Neuronetics and was an investigator in a trial sponsored by Janssen. He is presently principal investigator (PI) on an NIMH study that uses Neuronetics' transcranial magnetic stimulators. Dr. McDonald works for Emory University, which holds a patent for the transcranial magnetic stimulator that is used in the NIMH trial. He is also in an National Institute of Neurological Disorders and Stroke (NINDS) trial that is evaluating medication donated by Smith Kline (Paxil Controlled Release [CR]) and Wyeth (Effexor Extended Release [XR]).

Funding Information:
Dr. Fitzgerald has received research support from the National Health and Medical Research Council (NHMRC), National Alliance for Research on Schizophrenia and Depression (NARSAD), Beyond Blue, and Neuronetics, Ltd.

Funding Information:
Research Grant scheme, NARSAD, and Rebecca Cooper Medical Research Foundation.

Access

10.1016/j.biopsych.2009.06.027

OpenUrl availability

Full text

Cite this

O'Reardon, J. P., Solvason, H. B., Janicak, P. G., Sampson, S., Isenberg, K. E., Nahas, Z., McDonald, W. M., Avery, D., Fitzgerald, P. B., Loo, C., Demitrack, M. A., George, M. S., & Sackeim, H. A. (2010). Reply Regarding "Efficacy and Safety of Transcranial Magnetic Stimulation in the Acute Treatment of Major Depression: A Multisite Randomized Controlled Trial". Biological psychiatry, 67(2), e15-e17. https://doi.org/10.1016/j.biopsych.2009.06.027

O'Reardon, JP, Solvason, HB, Janicak, PG, Sampson, S, Isenberg, KE, Nahas, Z, McDonald, WM, Avery, D, Fitzgerald, PB, Loo, C, Demitrack, MA, George, MS & Sackeim, HA 2010, 'Reply Regarding "Efficacy and Safety of Transcranial Magnetic Stimulation in the Acute Treatment of Major Depression: A Multisite Randomized Controlled Trial"', Biological psychiatry, vol. 67, no. 2, pp. e15-e17. https://doi.org/10.1016/j.biopsych.2009.06.027

@article{a8933d94838f4222a78903aca2726ed8,

title = "Reply Regarding {"}Efficacy and Safety of Transcranial Magnetic Stimulation in the Acute Treatment of Major Depression: A Multisite Randomized Controlled Trial{"}",

author = "O'Reardon, {John P.} and Solvason, {H. Brent} and Janicak, {Philip G.} and Shirlene Sampson and Isenberg, {Keith E.} and Ziad Nahas and McDonald, {William M.} and David Avery and Fitzgerald, {Paul B.} and Colleen Loo and Demitrack, {Mark A.} and George, {Mark S.} and Sackeim, {Harold A.}",

note = "Funding Information: Dr. Isenberg has received grant support from the NIMH and Neuronetics; he is currently a full-time medical director at Wellpoint. Funding Information: Dr. Loo has received research support from the National Health and Medical Research Council (Australia), Neuronetics, New South Wales Schizophrenia Fellowship, Pfizer Neuroscience. Funding Information: Dr. Sackeim has received research support from the Cyberonics, MECTA, NARSAD, National Institute of Mental Health, and has acted as a consultant to Cyberonics, Eli Lilly, Magstim, MECTA, Neuronetics, NeuroPace, Novartis, and Pfizer. Funding Information: Dr. McDonald reports that he serves on the Executive Board of the Georgia Psychiatric Physicians Association and is Director of the Fuqua Center for Late-Life Depression, which advocate for geriatric psychiatry. Dr. McDonald is a member of the American Psychiatric Association (APA) task force on electroconvulsive therapy (ECT) and a member of the APA Council on Research. He reports consultant/speaker honorarium from Myriad, Bristol-Myers Squibb, and Janssen. He has received grant support from Boehinger Ingelheim and Neuronetics and was an investigator in a trial sponsored by Janssen. He is presently principal investigator (PI) on an NIMH study that uses Neuronetics' transcranial magnetic stimulators. Dr. McDonald works for Emory University, which holds a patent for the transcranial magnetic stimulator that is used in the NIMH trial. He is also in an National Institute of Neurological Disorders and Stroke (NINDS) trial that is evaluating medication donated by Smith Kline (Paxil Controlled Release [CR]) and Wyeth (Effexor Extended Release [XR]). Funding Information: Dr. Fitzgerald has received research support from the National Health and Medical Research Council (NHMRC), National Alliance for Research on Schizophrenia and Depression (NARSAD), Beyond Blue, and Neuronetics, Ltd. Funding Information: Research Grant scheme, NARSAD, and Rebecca Cooper Medical Research Foundation. ",

year = "2010",

month = jan,

day = "15",

doi = "10.1016/j.biopsych.2009.06.027",

language = "English (US)",

volume = "67",

pages = "e15--e17",

journal = "Biological psychiatry",

issn = "0006-3223",

publisher = "Elsevier USA",

number = "2",

}

TY - JOUR

T1 - Reply Regarding "Efficacy and Safety of Transcranial Magnetic Stimulation in the Acute Treatment of Major Depression

T2 - A Multisite Randomized Controlled Trial"

AU - O'Reardon, John P.

AU - Solvason, H. Brent

AU - Janicak, Philip G.

AU - Sampson, Shirlene

AU - Isenberg, Keith E.

AU - Nahas, Ziad

AU - McDonald, William M.

AU - Avery, David

AU - Fitzgerald, Paul B.

AU - Loo, Colleen

AU - Demitrack, Mark A.

AU - George, Mark S.

AU - Sackeim, Harold A.

N1 - Funding Information: Dr. Isenberg has received grant support from the NIMH and Neuronetics; he is currently a full-time medical director at Wellpoint. Funding Information: Dr. Loo has received research support from the National Health and Medical Research Council (Australia), Neuronetics, New South Wales Schizophrenia Fellowship, Pfizer Neuroscience. Funding Information: Dr. Sackeim has received research support from the Cyberonics, MECTA, NARSAD, National Institute of Mental Health, and has acted as a consultant to Cyberonics, Eli Lilly, Magstim, MECTA, Neuronetics, NeuroPace, Novartis, and Pfizer. Funding Information: Dr. McDonald reports that he serves on the Executive Board of the Georgia Psychiatric Physicians Association and is Director of the Fuqua Center for Late-Life Depression, which advocate for geriatric psychiatry. Dr. McDonald is a member of the American Psychiatric Association (APA) task force on electroconvulsive therapy (ECT) and a member of the APA Council on Research. He reports consultant/speaker honorarium from Myriad, Bristol-Myers Squibb, and Janssen. He has received grant support from Boehinger Ingelheim and Neuronetics and was an investigator in a trial sponsored by Janssen. He is presently principal investigator (PI) on an NIMH study that uses Neuronetics' transcranial magnetic stimulators. Dr. McDonald works for Emory University, which holds a patent for the transcranial magnetic stimulator that is used in the NIMH trial. He is also in an National Institute of Neurological Disorders and Stroke (NINDS) trial that is evaluating medication donated by Smith Kline (Paxil Controlled Release [CR]) and Wyeth (Effexor Extended Release [XR]). Funding Information: Dr. Fitzgerald has received research support from the National Health and Medical Research Council (NHMRC), National Alliance for Research on Schizophrenia and Depression (NARSAD), Beyond Blue, and Neuronetics, Ltd. Funding Information: Research Grant scheme, NARSAD, and Rebecca Cooper Medical Research Foundation.

PY - 2010/1/15

Y1 - 2010/1/15

UR - http://www.scopus.com/inward/record.url?scp=71649087928&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=71649087928&partnerID=8YFLogxK

U2 - 10.1016/j.biopsych.2009.06.027

DO - 10.1016/j.biopsych.2009.06.027

M3 - Letter

C2 - 19914602

AN - SCOPUS:71649087928

SN - 0006-3223

VL - 67

SP - e15-e17

JO - Biological psychiatry

JF - Biological psychiatry

IS - 2

ER -

Reply Regarding "Efficacy and Safety of Transcranial Magnetic Stimulation in the Acute Treatment of Major Depression: A Multisite Randomized Controlled Trial"

Bibliographical note

Access

OpenUrl availability

Other files and links

Cite this